Abstract Number: 1877 • 2012 ACR/ARHP Annual Meeting
Is the Amount of T and B Lymphocytes, Natural Killer Cells and Macrophages in Biopsies From Non-Ruptured Chronic Tendinopathic Achilles Tendons Predictive for Long Term Outcome? A >3 Years Prospective Study of 37 Patients
Background/Purpose: In biopsies from non-ruptured chronic tendinopathic Achilles tendons, presence of T and B lymphocytes, natural killer cells and macrophages has been reported. Whether the…Abstract Number: 1878 • 2012 ACR/ARHP Annual Meeting
Cognitive Manifestations of Fibromyalgia and Lupus
Background/Purpose: Similar cognitive complaints for patients with fibromyalgia and systemic lupus erythematosus (SLE) have been reported; however, inherently different deficits can share superficial similarities. The…Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…Abstract Number: 1840 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). Oral disease modifying anti-rheumatic drugs (DMARDs) are often used as a first-line treatment…Abstract Number: 1841 • 2012 ACR/ARHP Annual Meeting
Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
Background/Purpose: Reports suggest that a large proportion of patients who acquire and use biologic DMARD agents (biologics) to treat Rheumatoid Arthritis (RA) do not acquire…Abstract Number: 1842 • 2012 ACR/ARHP Annual Meeting
Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America
Background/Purpose: Studies on patients with severe rheumatoid arthritis (RA) are widely reported. However, limited data are available on patients with moderate disease activity (MOD). Recent…Abstract Number: 1843 • 2012 ACR/ARHP Annual Meeting
Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year Longitudinal Cohort
Background/Purpose: DMARDs are the standard of care for rheumatoid arthritis (RA), however multiple studies find that not all patients use these agents. We examined predictors…Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE). To be eligible for anti-TNF…Abstract Number: 1847 • 2012 ACR/ARHP Annual Meeting
Status of the Rheumatology Clinical Trials Portfolio: Data From Clinicaltrials.Gov
Background/Purpose: In an effort to provide a comprehensive listing of clinical trials Congress initiated the creation of the ClinicalTrials.gov (CT.gov) registry in 1997. In 2007…Abstract Number: 1848 • 2012 ACR/ARHP Annual Meeting
Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database
Background/Purpose: Joint replacement surgery patterns continue to change in patients with rheumatoid arthritis (RA), possibly reflecting the widespread adoption of disease modifying antirheumatic drugs, earlier…Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…Abstract Number: 1850 • 2012 ACR/ARHP Annual Meeting
Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy
Background/Purpose: Randomized controlled trials (RCTs) are considered the best research design for assessing healthcare intervention. Concerns have been raised about the increased likelihood of positive…Abstract Number: 1851 • 2012 ACR/ARHP Annual Meeting
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Background/Purpose: Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a source of significant morbidity/mortality. Health-care entities spend large amounts to prevent spread of MRSA. Most MRSA…
ACR Meeting Abstracts